DNase trials in cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Biochemistry
• Pharmacology

Background:

• Cystic Fibrosis (CF) is a genetic disorder characterized by severe pulmonary complications.
• High levels of deoxyribonucleic acid (DNA) in CF sputum increase its viscosity, contributing to disease progression.
• Recombinant deoxyribonuclease (rhDNase) targets DNA to reduce sputum viscoelasticity.

Purpose of the Study:

• To review in vivo clinical trials evaluating the safety and efficacy of recombinant deoxyribonuclease (rhDNase) in cystic fibrosis patients.
• To assess the impact of rhDNase on pulmonary function, infection rates, and quality of life.

Main Methods:

• Review of Phase 1, 2, and 3 clinical trials of rhDNase in cystic fibrosis patients.
• Analysis of safety data, pulmonary function tests (e.g., FEV1), infection exacerbation rates, and quality of life measures.
• Inclusion of data from longer-term, intermittent, and severe-patient studies.

Main Results:

• Phase 1 and 2 studies confirmed preliminary safety and showed improvements in pulmonary function.
• Phase 3 trials (968 patients) demonstrated significant FEV1 improvements (5.8-5.6%) with once or twice daily rhDNase.
• Treatment reduced infection exacerbations by 28-37% compared to placebo, with good safety and some quality of life benefits.

Conclusions:

• Recombinant deoxyribonuclease (rhDNase) is a safe and effective treatment for cystic fibrosis.
• rhDNase improves lung function and decreases infection risk in CF patients when used with conventional therapies.
• Further studies reviewed address long-term use, intermittent administration, and delivery systems.